5.30Open5.30Pre Close0 Volume146 Open Interest43.00Strike Price0.00Turnover85.68%IV1.88%PremiumMay 16, 2025Expiry Date4.41Intrinsic Value100Multiplier22DDays to Expiry0.89Extrinsic Value100Contract SizeAmericanOptions Type0.7197Delta0.0339Gamma7.35Leverage Ratio-0.0804Theta0.0166Rho5.29Eff Leverage0.0391Vega
Guardant Health Stock Discussion
Revolutionary Multi-Cancer Detection Data: Guardant Health Presents 18 Game-Changing Studies at AACR 2025
Major Breakthrough: Guardant Health's Cancer Tests Now Available to 350,000+ Canadians
To compare the stocks of Hims & Hers Health (HIMS), Guardant Health (GH), and Tempest Therapeutics (TEM) and determine which might be the most valuable to buy at their closing prices on March 11, 2025 (HIMS at $34.71, GH at $42.36, and TEM at $45.58), we’ll evaluate them based on key factors such as their business models, recent performance, valuation metrics, growth potential, and market sentiment. Since I don’t have real-...
Medicare Approves $1,495 Reimbursement for Groundbreaking Guardant Health Cancer Blood Test
NVDA (NVIDIA Corporation)
– Recommendation: Buy—undervalued with compelling growth prospects
– Entry Price Range: $115-$125
– Close Price Today: $120.15
– Comment: NVIDIA’s Q...
Ark Invest released its Big Ideas 2025 report, predicting that AI will completely transform multi-omics tools, drug development, and molecular diagnostics, while significantly improving the economic returns of pharmaceuticals. AI is expected to reduce drug development cost...
Pelosi's new holdings have doubled $Tempus AI (TEM.US)$ value in just a few weeks, and $Firefly Neuroscience (AIFF.US)$'s inclusion in NVIDIA's Connect program has also caused its stock price to soar.
In addition, DeepSeek's rapid rise has boosted the AI application sector, particularly in medicine/healthcare. Cathie Wood believes medical AI is undervalued, with untapped pot...
Guardant Health Secures Landmark Deal: 10,000 Cancer Screenings Set for Abu Dhabi
📊⚡️📊
No comment yet